8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 27, 2017)

Filed April 27, 2017For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on April 27, 2017, primarily to announce its first-quarter 2017 financial results. The report itself does not contain the detailed financial figures, but rather refers investors to a furnished press release (Exhibit 99.1) and supplemental information on their website (Exhibit 99.2) for the specific results. Investors seeking to understand BMY's performance in Q1 2017 should consult these accompanying documents for details on revenue, earnings, product sales, and forward-looking guidance. The key takeaway for investors is that BMY has officially communicated its Q1 2017 performance. While the 8-K serves as the formal notification of this event, the substance of the financial results, including any significant positive or negative developments, will be found within the press release and supplementary materials. Investors should pay close attention to these exhibits for performance metrics and any strategic updates.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) filed an 8-K on April 27, 2017.
  • 2The filing announces the release of the Company's first-quarter 2017 financial results.
  • 3Detailed financial results are provided in a furnished press release (Exhibit 99.1).
  • 4Additional supplemental information is available on the BMY website (Exhibit 99.2).
  • 5Investors are directed to these external documents for a comprehensive understanding of Q1 2017 performance.
  • 6The 8-K serves as a notification mechanism for the release of financial results.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Bristol-Myers Squibb's financial results for the first quarter of 2017. The filing itself references a press release and supplemental website information where the detailed results can be found.

The actual Q1 2017 financial results are located in the press release furnished as Exhibit 99.1 to this 8-K filing and in the supplemental information posted on the Bristol-Myers Squibb website (www.bms.com), furnished as Exhibit 99.2.

No, this 8-K filing itself does not contain the detailed financial figures. It serves as a notification that the results have been released and directs investors to the accompanying press release (Exhibit 99.1) and supplemental website information (Exhibit 99.2) for those details.

This report covers the financial results for the first quarter of 2017.